Literature DB >> 30050993

Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.

Chun-Nan Yeh1.   

Abstract

Entities:  

Year:  2018        PMID： 30050993      PMCID： PMC6043756          DOI： 10.21037/tgh.2018.06.03

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  5 in total

1.  [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].

Authors:  Yurina Saito; Tsuyoshi Takahashi; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gan To Kagaku Ryoho       Date:  2018-01

2.  Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.

Authors:  Alexander J Eckardt; Ortwin Klein
Journal:  Transl Gastroenterol Hepatol       Date:  2018-02-28

3.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

4.  A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.

Authors:  Chun-Nan Yeh; Ming-Huang Chen; Yen-Yang Chen; Ching-Yao Yang; Chueh-Chuan Yen; Chin-Yuan Tzen; Li-Tzong Chen; Jen-Shi Chen
Journal:  Oncotarget       Date:  2017-07-04

5.  Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Authors:  Myoung Kyun Son; Min-Hee Ryu; Joon Oh Park; Seock-Ah Im; Tae-Yong Kim; Su Jin Lee; Baek-Yeol Ryoo; Sook Ryun Park; Yoon-Koo Kang
Journal:  Cancer Res Treat       Date:  2016-07-19       Impact factor: 4.679
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.